MIR196A2 rs11618034: What Your Genotype Means
The rs11618034 polymorphism is a non-coding single nucleotide variant located in the precursor sequence of the microRNA gene MIR196A2. Multiple epidemiological studies and meta-analyses have evaluated this locus for potential associations with cancer susceptibility, particularly across digestive and respiratory malignancies. However, the scientific evidence remains limited and mixed across diverse ancestral populations, meaning it represents a modest statistical correlation rather than a direct clinical indicator.
What each genotype means
Common MIR196A2 genotype
This genotype represents the most common form of the MIR196A2 variant in many populations. Research into this genetic region has explored potential links to cancer susceptibility, though findings remain inconsistent across different studies and cancer types. This result should be viewed as a general genetic observation rather than a diagnostic indicator of health risk.
This is the most frequent genotype globally, though exact percentages vary significantly by ancestral background.
Heterozygous MIR196A2 genotype
Carrying one copy of each allele is common and has been the subject of numerous association studies regarding cancer risk. Because the evidence linking this variant to specific health outcomes is limited and often conflicting, this genotype does not provide a clear clinical prediction. It is important to interpret these findings as part of a complex genetic landscape rather than a direct cause of disease.
This genotype is found in a significant portion of the global population, frequently appearing in both European and non-European cohorts.
Variant MIR196A2 genotype
This genotype represents the less common variant at this position, which has been investigated for potential associations with susceptibility to various cancers, including lung and breast cancer. Current scientific literature shows mixed results, and the clinical significance of this specific genotype remains uncertain. Please consult with a healthcare professional if you have concerns about your personal or family health history.
This genotype is less common than the CC or CT configurations, with frequencies typically ranging between 0.20 and 0.45 for the minor allele depending on the population.
Understanding rs11618034 and the MIR196A2 Gene
The single nucleotide polymorphism (SNP) cataloged as rs11618034 is situated in the non-coding genetic locus of MIR196A2, a gene located on human chromosome 12 that encodes microRNA-196a-2. MicroRNAs are small, non-coding RNA molecules that typically do not code for proteins themselves, but instead function as critical post-transcriptional regulators of gene expression. By binding complementary sequences on messenger RNA transcripts, microRNAs modulate target stability and protein translation. Alterations within pre-microRNA stem-loop structures can affect the maturation and processing of mature microRNAs, which in turn influences downstream regulatory cascades that control cellular differentiation, proliferation, and programmed cell death.
Research on Cancer Susceptibility and Biological Evidence
A substantial body of genetic epidemiology literature, encompassing dozens of case-control studies and subsequent meta-analyses, has explored whether variants in MIR196A2 alter the risk of developing malignant tumors. Research has centered primarily on common epithelial cancers, such as lung, colorectal, gastric, and breast malignancies. While functional investigations suggest that variations at this locus might alter mature miR-196a processing efficiency or target binding affinity, the epidemiologic evidence supporting disease susceptibility remains classified as limited. Findings across independent cohorts are frequently inconsistent, with several studies identifying modest risk elevations, others observing protective correlations, and others finding no statistically significant relationship.
Ancestry-Specific Patterns and Global Frequencies
A critical nuance in research regarding rs11618034 and closely related MIR196A2 loci is the marked variation across human populations. The variant is globally prevalent, with minor allele frequencies typically ranging between 0.20 and 0.45 across broad ancestral groups. However, the statistical correlations highlighted in published meta-analyses are disproportionately concentrated in cohorts of East Asian descent, where associations with specific gastrointestinal and lung tumors have been reported most consistently. In contrast, studies examining European and African ancestry cohorts frequently report null findings, demonstrating that genetic background, linkage disequilibrium, and environmental interactions heavily shape these statistical observations.
What Consumers Can and Cannot Conclude
Learning your rs11618034 genotype does not constitute a clinical diagnosis, nor does it predict the certain development or absence of any disease. Single non-coding variants have tiny individual effect sizes and explain only a negligible portion of overall absolute cancer risk, which is predominantly driven by complex multifactorial elements such as lifestyle, family history, environmental exposures, and age. Genetic testing results from consumer panels for this SNP cannot replace established clinical screenings, including routine mammography, colonoscopy, or cervical screening. Anyone with concerns about hereditary cancer risks should speak with a genetic counselor or licensed physician to evaluate personal family medical history rather than relying on isolated non-coding polymorphisms.
How common is this variant?
The variant is common globally, exhibiting minor allele frequencies typically between 0.20 and 0.45 across diverse ancestries, with higher minor allele representation frequently reported in East Asian populations.
Frequently asked questions
What is the MIR196A2 rs11618034 variant?
The rs11618034 variant is a single nucleotide polymorphism located within the non-coding MIR196A2 gene on chromosome 12. MIR196A2 encodes a regulatory microRNA that manages how specific proteins are expressed in human cells.
Does having the rs11618034 variant mean I will get cancer?
No, it does not. The variant is only linked to modest statistical risk variations in population-level studies, with many conflicting results across different ancestries. It is not a pathogenic mutation and cannot diagnose or predict disease in an individual.
Why do study results differ between ethnic groups?
Genetic architecture, allele frequencies, and linkage patterns differ significantly across diverse ancestral populations. In addition, varying environmental factors and differences in study sample sizes often produce conflicting results between European, Asian, and other regional cohorts.
Should I share this genetic result with my doctor?
Because rs11618034 currently lacks established clinical utility, medical professionals do not use it to guide screening or treatment decisions. If you have concerns about your cancer risk, discuss your overall family history and standard screening guidelines with your healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11618034?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29